News

NICE is told to break its close links with drug industry

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7416.637 (Published 18 September 2003) Cite this as: BMJ 2003;327:637
  1. Zosia Kmietowicz
  1. London

    The National Institute for Clinical Excellence (NICE) has been advised by an independent review to break its close links with the drug industry and to make its processes more transparent.


    Embedded Image

    Kees de Joncheere, WHO's regional adviser for health technology and pharmaceuticals (left) and Professor Michael Rawlins, NICE chairman

    Credit: WHO

    Experts from the World Health Organization who carried out the review have advised NICE that, to avoid any possible bias, pharmaceutical physicians should not be members of committees that make judgments on particular drugs …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe